Roche has signed a contract with Dyno Therapeutics, a gene therapy vector

signed a partnership agreement with Dyno Therapeutics to develop adenovirus (AAV) vectors for gene therapy for central nervous system (CNS) disease and liver targeted therapy.Under the terms of the agreement, Dyno will design new AAV shells with improved gene therapy functional characteristics, while Roche and its subsidiary Spark Therapeutics will be responsible for preclinical, mid-clinical and commercialization activities for candidate products using new types of gene therapy products.Roche will make an unanclosed advance payment to Dyno, as well as additional payments during the cooperative research phase.In addition, Dyno is eligible for clinical and sales advances and royalties for any proceeds of the product, all of which may exceed $1.8 billion.Dyno's CapsidMap platform is used to identify new AAV enclosures - cell-targeted protein shells for viral vectors - and, in addition to improving packaging capacity and manufacturability, optimizes tissue targeting and immunity evasion.“ We believe in the potential of gene therapy and are excited to bring together experts from Roche, Spark and Dyno to develop the next generation of gene therapies," said James Sabry, head of Roche Pharmaceutical Partners.“ Dyno's innovative AI-based approach to designing optimized AAV vectors will further complement and reinforce our advances in gene therapy. We look forward to using Dyno's technology to develop new and innovative therapies for patients with central nervous system and liver targeted therapies. The
(cyy123.com)original source:
Rogers deal with Dyno Therapeutics for gene therapy vectors